All In Biotech

Drug Trial Radar · NCT03417102

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX

Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

60

Actual

Start

Feb 14, 2018

Primary completion

Nov 25, 2020

Study completion Jun 23, 2021

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).

Conditions

  • Hemophilia A
  • Hemophilia B

Interventions

  • fitusiranDrug

    solution for injection; by subcutaneous (SC) injection

  • Bypassing agentsDrug

    solution for injection; by intravenous (IV) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest
  2. Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest

Locations

58 sites in 17 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 0117

    Phoenix, Arizona

  • Investigational Site Number 0139

    Los Angeles, California

  • Investigational Site Number 0135

    Orange, California

  • Investigational Site Number 0137

    San Diego, California

  • Investigational Site Number 0128

    Gainesville, Florida

  • Investigational Site Number 0115

    Jacksonville, Florida

  • Investigational Site Number 0105

    Miami, Florida

  • Investigational Site Number 0103

    Tampa, Florida

  • Investigational Site Number 0119

    New Orleans, Louisiana

  • Investigational Site Number 0136

    Baltimore, Maryland

  • Investigational Site Number 0111

    Las Vegas, Nevada

  • Investigational Site Number 0104

    Philadelphia, Pennsylvania

  • Investigational Site Number 6101

    Camperdown, Australia

  • Investigational Site Number 6104

    Clayton, Australia

  • Investigational Site Number 1102

    Montreal, Canada

  • Investigational Site Number 8604

    Beijing, China

  • Investigational Site Number 8602

    Guangzhou, China

  • Investigational Site Number 8605

    Hangzhou, China

  • Investigational Site Number 8603

    Shanghai, China

  • Investigational Site Number 8601

    Tianjin, China

  • Investigational Site Number 3303

    Lyon, France

  • Investigational Site Number 3301

    Rouen, France

  • Investigational Site Number 4905

    Frankfurt am Main, Germany

  • Investigational Site Number 4906

    Leipzig, Germany

  • Investigational Site Number 9102

    Bangalore, India

  • Investigational Site Number 9108

    India, India

  • Investigational Site Number 9104

    Jaipur, India

  • Investigational Site Number 9106

    Lucknow, India

  • Investigational Site Number 9103

    Pune, India

  • Investigational Site Number 9111

    Pune, India

  • Investigational Site Number 9105

    Vellore, India

  • Investigational Site Number 3901

    Florence, Italy

  • Investigational Site Number 3904

    Padua, Italy

  • Investigational Site Number 8110

    Japan, Japan

  • Investigational Site Number 8103

    Kita Kyushu-Shi, Japan

  • Investigational Site Number 6003

    Kota Kinabalu, Malaysia

  • Investigational Site Number 6004

    Malaysia, Malaysia

  • Investigational Site Number 2701

    Parktown, South Africa

  • Investigational Site Number 2703

    Polokwane, South Africa

  • Investigational Site Number 2702

    Port Elizabeth, South Africa

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.